Related Experiment Video
Updated: May 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Pharmacodynamics of multi-dose low molecular weight heparin in healthy horses
Dorothy D Whelchel1, Brett S Tennent-Brown, Steeve Giguère
1Department of Large Animal Medicine, University of Georgia College of Veterinary Medicine, Athens, Georgia, USA.
Objectives:
To compare the pharmacodynamics of once daily and twice daily administration of low molecular weight heparin (LMWH) administration in horses.
Study Design:
Randomized cross over study.
Animals:
Adult mixed breed healthy mares (n = 6).
Methods:
LMWH (dalteparin) was administered (50 U/kg subcutaneously) either every 12 or 24 hours for 3 consecutive days. Anti-factor Xa activity was measured before and at select time points after LMWH administration. Packed cell volume (PCV), platelet count, partial thromboplastin time (PTT), and anti-thrombin (AT) activity were monitored throughout the study.
Results:
No changes in PCV, platelet count, or AT activity were detected with either frequency of daily LMWH administration. Values for PTT increased throughout the study but never exceeded the normal reference interval. Anti-factor Xa activity was maintained within or above the suggested thromboprophylactic range (0.1-0.2 U/mL) when LMWH was administered twice daily, but fell below this range ≈ 16 hours after administration when given once daily. For both once and twice daily LMWH administration, the area under the curve was significantly greater after the last dose of LMWH when compared to the first dose.
Conclusions:
Administration of LMWH once or twice daily for 3 consecutive days appears to be safe in healthy adult horses. Anti-factor Xa activity was maintained within or above the suggested thromboprophylactic range for 24 hours with twice daily LMWH administration but not with once daily administration.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Dosage Regimens: Partial Pharmacokinetic Parameters

